Actively Recruiting
ctDNA in HER2+ EBC Neoadjuvant Treatment
Led by Shanghai Jiao Tong University School of Medicine · Updated on 2026-03-24
60
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a randomized, open-label, multicenter clinical study for patients with early or locally advanced (T≥2cm, N0-3, M0) HER2-positive breast cancer, aiming to compare the peripheral blood ctDNA clearance of neoadjuvant pyrotinib + trastuzumab + docetaxel and pertuzumab + trastuzumab + docetaxel for one course and to evaluate the therapeutic effectiveness of four courses of neoadjuvant therapy
CONDITIONS
Official Title
ctDNA in HER2+ EBC Neoadjuvant Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically diagnosed Stage II-III HER2-positive breast cancer with a primary tumor larger than 2 cm
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Normal kidney, liver, bone marrow, and heart function, including left ventricular ejection fraction (LVEF) ≥ 55% by echocardiography
- No prior treatment for breast cancer
You will not qualify if you...
- Bilateral or metastatic breast cancer
- History of other cancers
- Severe cardiovascular disease
- Allergy to any of the study treatments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital
Shanghai, China, 200025
Actively Recruiting
Research Team
H
Haoyu Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here